|BET bromodomain inhibition as a therapeutic strategy to target c-Myc|
JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ...
Cell 146 (6), 904-917, 2011
|International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma|
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
|Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors|
A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ...
J Clin Oncol 23 (34), 8580-7, 2005
|International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma|
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
|New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes|
G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ...
Journal of clinical oncology 30 (36), 4541-4549, 2012
|Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid|
MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ...
Annals of Oncology 20 (1), 117-120, 2008
|Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid|
MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, ...
haematologica 91 (7), 968-971, 2006
|Pathogenesis and treatment of renal failure in multiple myeloma|
MA Dimopoulos, E Kastritis, L Rosinol, J Blade, H Ludwig
Leukemia 22 (8), 1485, 2008
|Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis|
E Kastritis, AD Wechalekar, MA Dimopoulos, G Merlini, PN Hawkins, ...
Journal of Clinical Oncology 28 (6), 1031-1037, 2010
|Diagnosis of monoclonal gammopathy of renal significance|
F Bridoux, N Leung, CA Hutchison, G Touchard, S Sethi, JP Fermand, ...
Kidney international 87 (4), 698-711, 2015
|Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia|
MA Dimopoulos, MA Gertz, E Kastritis, R Garcia-Sanz, EK Kimby, ...
J Clin Oncol 27 (1), 120-126, 2009
|A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis|
AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ...
Blood 121 (17), 3420-3427, 2013
|Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the …|
E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, ...
Leukemia 23 (6), 1152, 2009
|European Myeloma Network guidelines for the management of multiple myeloma-related complications|
E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ...
haematologica 100 (10), 1254-1266, 2015
|Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone|
E Kastritis, A Anagnostopoulos, M Roussou, S Toumanidis, C Pamboukas, ...
Haematologica 92 (10), 1351-1358, 2007
|How I treat monoclonal gammopathy of renal significance (MGRS)|
JP Fermand, F Bridoux, RA Kyle, E Kastritis, BM Weiss, MA Cook, ...
Blood 122 (22), 3583-3590, 2013
|Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents|
E Kastritis, A Anagnostopoulos, M Roussou, D Gika, C Matsouka, ...
Haematologica 92 (4), 546-549, 2007
|VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results …|
MA Dimopoulos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, ...
Journal of Clinical Oncology 27 (36), 6086-6093, 2009
|International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment|
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
J Clin Oncol 34 (13), 1544-1557, 2016
|Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop|
RG Owen, RA Kyle, MJ Stone, AC Rawstron, V Leblond, G Merlini, ...
British journal of haematology 160 (2), 171-176, 2013